STEP 3 Trial The STEP 3 trial included 611 adults who were overweight or had obesity
(Novo Nordisk, the maker of Ozempic, previously told TODAY.com in a statement that it does not support off-label use of its medications.) Examples of other similar drugs include Mounjaro, approved for diabetes, and Zepbound, approved for obesity, both made by Eli Lilly
Monitor for hypoglycaemia, cardiovascular symptoms, severe abdominal pain, allergic reactions, and unusual side effects following suspected intravenous administration
Description GL-2 TZ is a premium research peptide often classified as a Dual Agonist. It represents a significant advancement over single-receptor peptides by targeting both the GIP (Glucose-dependent Insulinotropic Polypeptide) and GLP-1 (Glucagon-like Peptide-1) receptors
[6] [7] This formulation requires specific manufacturing processes that result in the tablet's characteristic white to light yellow appearance